SCHEMBL17799691

SCHEMBL17799691

O=C(N[C@H]1CC[C@H]1c1ccc(F)cc1F)c1cccs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ ATM Q13315 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ RAB9A P51151 6/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ NPC1 O15118 4/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ HPGD P15428 3/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ TP53 P04637 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17799700 0.82 HCRTR1 (0.49) L3MBTL1KMT2ALMNAPKMGAA
SCHEMBL17799696 0.81 ALDH1A1 (0.38) TSHRHSD17B10L3MBTL1RAB9AMEN1
SCHEMBL17799693 0.80 TAS1R3 (0.47) LMNATP53GAA
SCHEMBL17799701 0.80 TAS1R3 (0.39) ATML3MBTL1HPGD
SCHEMBL17799722 0.80 HPGD (0.41) L3MBTL1RAB9AHPGD
SCHEMBL17799747 0.80 TAS1R3 (0.39) L3MBTL1RAB9ANPC1HPGD
SCHEMBL17799753 0.80 F10 (0.39) RAB9AMEN1KMT2AALDH1A1HPGD
SCHEMBL17799692 0.80 HCRTR1 (0.49) L3MBTL1NPC1ALDH1A1LMNAGAA
SCHEMBL17799731 0.80 TSHR (0.54) TSHRHSD17B10ATML3MBTL1RAB9A
SCHEMBL17799646 0.79 MC1R (0.45) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS TSHR 3672/4885HSD17B10 2938/4885ATM 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback